AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination
Michael C. Haffner(Memorial Sloan Kettering Cancer Center), Srinivasan Yegnasubramanian(Johns Hopkins University), Steven S. An(Johns Hopkins University), Edward M. Schaeffer(Northwestern University), William G. Nelson(Johns Hopkins University), David Esopi(AstraZeneca (United States)), Harrison Tsai(Boston Children's Hospital), Ajay Vaghasia(Sidney Kimmel Comprehensive Cancer Center), Paula J. Hurley(Vanderbilt University Medical Center), Hong Lam(Johns Hopkins University), Alcides Chaux(Johns Hopkins University), Susmita Ghosh(The University of Texas MD Anderson Cancer Center), George J. Netto(University of Pennsylvania), William B. Isaacs(Unknown), Debika Biswal Shinohara(Johns Hopkins University), Brian W. Simons(Johns Hopkins University), Jessica Hicks(Johns Hopkins University), Meltem Ö. Gürel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nicolas Wyhs(Johns Hopkins University), Angelo M. De Marzo(Johns Hopkins University), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Nicole Castagna(Johns Hopkins University), Tamara L. Lotan(Johns Hopkins University)
Cited by 50
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k